Parcourir par auteur "Markopoulos, C."
Voici les éléments 1-2 de 2
-
Breast cancer risk in relation to most prevalent IgE specific antibodies: A case control study in Greece
Petridou, E. T.; Chavelas, C.; Dikalioti, S. K.; Dessypris, N.; Terzidis, A.; Nikoulis, D. I.; Markopoulos, C.; Papadiamantis, Y.; Germenis, A. E. (2007)Background: This study aims to explore the debatable role of allergy in breast cancer (BC) by using country-specific biological markers, namely levels of the most prevalent allergen -specific immunoglobulin E in Greece. ... -
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
Fountzilas, G.; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, P.; Karanikiotis, C.; Bafaloukos, D.; Kosmidis, P.; Samantas, E.; Varthalitis, I.; Pavlidis, N.; Pectasides, D.; Dimopoulos, M. A. (2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...